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For a long time, white adipose tissue (WAT) has been regarded as an inert tissue for energy 
storage. With the rapidly rising incidence of the metabolic syndrome – obesity, diabetes mellitus 
type II, and hypertension – in the industrialized world, these diseases have attracted increasing 
attention in research and health politics. In parallel, WAT was recognized as an active endocrine 
and paracrine organ that plays an important role in the metabolic syndrome 1. 
Various studies within the past decade indicated that WAT in obesity is characterized by 
a chronic low-grade inflammation with secretion of inflammatory cytokines and chemokines 
(Fig. 1): Tumor necrosis factor-α (TNF-α) was identified as the first molecular link between 
inflammation and obesity by Hotamisligil and coworkers: Expression of this cytokine was 
increased in WAT of obese mice 2 and correlated with obesity-induced insulin resistance 3. 
Interleukin-6 (IL-6) is another cytokine critically involved in the pathogenesis of obesity and insulin 
resistance. The serum levels of IL-6 positively correlate with obesity in humans and predict the 
risk of developing insulin resistance and diabetes mellitus type 2 4 . IL-6 is produced by a variety 
of metabolic tissues including WAT, hepatocytes, β-cells, and skeletal muscle. Thus, circulating 
IL-6 could mediate a crosstalk between these organs resulting in a downward spiral towards 
systemic insulin resistance and decreased insulin secretion 5. Furthermore, obesity was found to 
be associated with macrophage accumulation in murine and human WAT 6. Chemokines such as 
CCL2/monocyte chemoattractant protein-1 (MCP-1) and CCL3/macrophage inflammatory protein-
1a (MIP-1α) were reported to be increased in WAT of obese mice and to contribute to insulin 
resistance and macrophage recruitment 7. Recently, a causal relationship between obesity, WAT 
inflammation, and insulin resistance was characterized for MCP-1 and its receptor CCR2: MCP-1 
enhanced macrophage infiltration in WAT, insulin resistance, and hepatic steatosis in obesity 8. 
Obese mice with CCR2 deficiency exhibited decreased WAT inflammation and improved 
systemic insulin resistance 9. The close relationship between WAT mass, the size of adipocytes in 
obesity, the number of macrophages in WAT, as well as the level of inflammatory cytokines and 
chemokines in WAT suggests a paracrine crosstalk involving adipose tissue macrophages and 
adipocytes. In addition, concomitant effects on liver steatosis and systemic insulin resistance 
imply more widespread, endocrine effects of WAT inflammation in obesity. 
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We learn now from Wu and colleagues in this issue of Circulation 10 that T cells and the 
chemokine CCL5/Regulated on Activated Normal T Cell Expressed and Secreted (RANTES) are 
also increased in WAT in the setting of murine and human obesity (Fig. 1). A previous study did 
not find elevated CD3-positive cells by immunohistochemistry in WAT of both genetic and high-fat 
diet-induced mouse models of obesity 7. Wu and colleagues characterized T cells via flow 
cytometry, mRNA, and immunofluorescence stainings in WAT samples obtained from obese mice 
and humans. The discrepancy between the two studies remains to be clarified; it may relate to 
the lower fat content (41 vs. 60%) or to the longer diet exposure (24 vs. 16 weeks) of mice 
subjected to diet-induced obesity in the current study. 
Furthermore, Wu and coauthors report that both mRNA and protein levels of RANTES 
were increased in a gender-dependent fashion in WAT of obesity. RANTES levels were 
particularly elevated in male mice in the stromal/vascular fraction of WAT as compared to its 
adipocyte fraction. In addition, monoclonal antibodies directed against RANTES reduced T cell 
chemotaxis induced by media conditioned by WAT isolated from obese male mice. These 
findings underline the role of RANTES-induced T cell chemotaxis by WAT in obesity and suggest 
an opportunity for pharmacological interventions. Interestingly, obese female mice exhibited less 
WAT inflammation, lower levels of RANTES and CCR5 expression, and were less insulin 
resistant than their male counterparts. The reason of this phenomenon remains to be determined. 
With regard to RANTES receptors, the authors find that CCR5, the major receptor for 
RANTES and CCR3 were both induced in WAT of obesity by its stromal/vascular as well as its 
adipocyte fraction. This increase in RANTES, CCR5, and CCR3 in WAT of obesity may create a 
positive auto- and paracrine feedback loop, while providing a potent signal for the recruitment of 
macrophages and T cells. 
Ballantynes’ group further reports higher expression of RANTES in visceral compared 
with subcutaneous WAT of morbidly obese humans. An abnormal increase in visceral fat 
constitutes a prominent risk factor for atherosclerosis and was found to be associated with 
elevation of the inflammation marker CRP 11.  
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In summary, Wu et al. report for the first time an accumulation of T cells in obese WAT 
that is gender-dependent and associated with increased expression of RANTES as well as its 
main receptor CCR5. What is the potential impact of these findings? 
 
Other organs involved in metabolic responses are likely to be affected by similar cellular, 
molecular or endocrine pathways (Fig. 1) as suggested recently by Lazar 12. The most striking 
similarities relate to atherosclerosis. WAT in obesity is characterized by a low-grade chronic 
inflammation 13. Likewise, atherosclerosis is recognized as a chronic inflammatory disease in 
which macrophages and lymphocytes play a crucial role 14. The chemokine MCP-1 or its receptor 
CCR2 mediate deleterious effects in obesity 8, 9. In parallel, MCP-1 or CCR2 deficiency decreased 
atherogenesis in atherosclerosis-prone mice 15, 16. The current findings by Wu and colleagues 
match a study by Mach’s group: They showed that RANTES expression colocalized with 
macrophages and T cells within murine atherosclerotic lesions and that the RANTES antagonists 
Met-RANTES reduced progression of atherosclerosis in mice 17. These findings suggest that 
pharmacological inhibition of chemokines may exert beneficial pleiotropic effects in several 
metabolically active organs. In particular, it would be interesting to determine whether RANTES 
antagonists affect diet-induced WAT inflammation and insulin resistance. Similar pharmacological 
interventions or genetic approaches that modulate RANTES or its receptors in mice would also 
clarify the causal role of RANTES related to metabolic and inflammatory effects following diet-
induced obesity. 
A paracrine crosstalk between atherosclerosis and periadventitial adipose tissue 
releasing inflammatory chemokines and cytokines was suggested by studies correlating human 
and rodent tissue samples 18, 19. The concept that adipocytes and macrophages integrate 
metabolic and immune responses through shared mechanisms has been formulated 
previously 13. The current study by Ballantynes’ group suggests that some of these responses 
may also be shared by T cells. 
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The liver constitutes another metabolically active organ and has been shown to be 
affected by genetic modulations of both MCP-1 or CCR2 8, 9. In the current study, RANTES 
mRNA was less induced in liver than in WAT suggesting that RANTES may exert only minor 
alterations in liver metabolism of diet-induced obesity. However, the relevance of RANTES in this 
context remains to be determined. 
The pancreas is also at the crossroads of metabolism. Chronic hyperglycemia in diabetes 
mellitus type II is detrimental to pancreatic β-cells leading to impaired insulin secretion. Donath’s 
group demonstrated the critical role of inflammatory cytokines in this context. They showed that 
high glucose increased interleukin-1β (IL-1β) levels and impaired β-cell function. An IL-1 receptor 
antagonist protected cultured human islets from these deleterious effects 20. Investigating the role 
of RANTES in this context may be another interesting avenue to pursue. 
 
In conclusion, this study supports the paradigm that inflammatory cytokines and 
chemokines, macrophages and T cells are important players in the inflammation of adipose tissue 
in obesity. It also suggests paracrine and endocrine interactions among organs involved in the 
metabolic syndrome. A better understanding of these local and systemic interactions will have 
major implications for decreasing morbidity and mortality of its associated diseases. 
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Figure Legend 
 
Figure 1. Inflammatory chemokines and cytokines in obesity and the metabolic syndrome. 
Obesity leads to chronic low-grade inflammation of white adipose tissue (WAT). Activated 
macrophages (macroΦ) and T cells within WAT produce increased levels of inflammatory 
chemokines such as CCL2/monocyte chemoattractant protein-1 (MCP-1) and CCL5/Regulated 
on Activated Normal T Cell Expressed and Secreted (RANTES) as well as cytokines such as 
tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1 β), and IL-6. Release of these mediators of 
inflammation is increased by the WAT in obesity and may affect other organs involved in the 
metabolic syndrome by paracrine or endocrine effects. For example, these chemokines/cytokines 
may by promote atherosclerotic plaque formation, liver steatosis, and pancreatic β-cell 
degeneration leading to diabetes mellitus type II. Many of these chemokines/cytokines are also 
produced by these organs and have been shown to play a role, particularly in atherosclerosis. 
The degree of local and systemic interactions between the different organs affected by the 
metabolic syndrome remains to be determined. 
